Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib and Obinutuzumab in Relapsed/Refractory CLL
NCT02537613Phase 1Active, not recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Dec 2015
- Primary completion
- Mar 2020
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ibrutinib and obinutuzumab in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) (3 arms), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Grade 3-5 Treatment-related Toxicity Rate. Started Dec 2015; status: active, not recruiting.
02
Drugs
ibrutinibobinutuzumab
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT02537613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02537613.